Group 1 - The core viewpoint of the article highlights that Tonghe Pharmaceutical (300636.SZ) anticipates rapid growth in new products in the first half of 2025, reaching 195 million yuan [1] - The high-end regulatory market is expected to contribute 160 million yuan, while emerging markets are projected to add 35 million yuan to the growth [1] - The company expects a positive growth trend in the future as a result of a concentration of new product patents expiring over the past three years [1]